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selected for the development of mapping algorithms. The linear regression model 
had best model fit. However, the SEM that incorporated item level data for ordinal 
responses to each instrument showed better predictive performance, especially at 
the lower end of the EQ-5D distribution. ConClusions: This study demonstrates 
the flexibility of SEMs for the development of mapping algorithms. The models 
developed showed comparable predictive performance to existing models in the 
published literature.
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Evaluation of MEthods foR thE inclusion of REal WoRld EvidEncE in 
nEtWoRk MEta-analysis – a casE study in MultiPlE sclERosis
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objeCtives: Network Meta-Analysis (NMA) is becoming a key component of sub-
missions to reimbursement agencies world-wide, especially when there is limited 
head-to-head evidence for multiple technologies. However, almost all NMAs only 
consider Randomised Controlled Trials (RCTs) even though there may be consid-
erable Real World Evidence (RWE) available – for example observational studies 
or registry-based studies. Evaluation of methods to enable the inclusion of RWE, 
especially in the light of the changing nature of RCTs from both a regulatory and 
reimbursement perspective, is considered here. Methods: RCTs and RWE stud-
ies were searched for using standard filters and databases up to, and including, 
the regulatory approval of Fingolimod by the European Medicines Agency (EMA) in 
2011 for Multiple Sclerosis (MS). A number of NMAs were then conducted and which 
included; only RCTs, both RCTs and RWE (accepted at face-value), both RCTs and 
RWE but including an additional level in the NMA hierarchical model to represent 
the different study designs, and finally both RCTs and RWE but adjusting the RWE 
for potential biases. Results: Identification of RWE in addition to RCTs in this 
MS example significantly increased the number of studies (and comparisons) that 
were potentially included in the NMA. Whilst the inclusion of the additional RWE 
led to a reduction in the level of uncertainty surrounding most effect estimates, 
this depended on the method of inclusion adopted for the RWE, and the extent to 
which biases were adjusted for. ConClusions: This initial evaluation of methods 
for the inclusion of RWE in NMAs indicates that methods of adjustment for the 
potential biases in RWE can have a significant impact on the level of uncertainty. 
Consequently further work investigating both empirical evidence for such biases 
and methods of elicitation from experts on the extent of biases associated with 
individual RWE studies is warranted.
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fREquEntist aPPRoach foR dEtEcting hEtERogEnEity in MEta-
analysis PaiR-WisE coMPaRisons: EnhancEd q-tEst usE By using i2 
and h2 statistics
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objeCtives: In meta-analysis, model selection is an important criterion which 
needs to be tested and validated by strong statistical evidence. The Cohran’s Q-test 
allows in theory to decide between random-effect and fixed-effect models. Due 
to the highly conservative nature of this test, three statistics have been built to 
estimate the heterogeneity between studies to lead the model decision: the I2, the 
H2 and the R2. We conducted a review of the Q-test utility in diverse scenarios with 
a comparison of three different methods to estimate the heterogeneity between 
studies. Methods: Based on the global formulation of the Cochran’s Q-test, we 
proposed to analyse jointly the first error species and the second error species in 
different scenarios based on the number of studies included in each meta-analysis. 
The goal was to determine the reliability of the Q-test in extreme situations but also 
to give some benchmark for the reliability of this test. We use simulation methods 
to analyse the three different methods for calculating the between-study variance 
compared to the real value of heterogeneity. We also compared different arbitrary 
levels for model selection using these statistics in different scenarios. Results: The 
Cochran’s Q-test is too conservative with a large number of studies and concludes to 
the presence of heterogeneity whatever the situation is when the number of studies 
is higher than 18. In comparison, the different statistics have an average value con-
versely linked with the number of studies in case of non-heterogeneity: the higher 
the number of studies, the lower the statistics’ average values. ConClusions: The 
I2 and H2statistics can eventually enhance the use of Cochran’s Q-test by solving 
conservative issue associated with this test. The model selection can, eventually, be 
led by benchmark of these statistics jointly with the Cochran’s Q-test.
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thE usE and accEPtancE of novEl statistical analysEs to suPPoRt 
tEchnology suBMissions to hta authoRitiEs
Batson S., Mitchell S.A., King D.
Abacus International, Bicester, UK
objeCtives: Indirect comparisons are increasingly accepted to model the clini-
cal- and cost-effectiveness of treatments. The purpose of this study was to (i) 
assess the literature reporting on the use of novel statistical methods [simulated 
treatment comparison (STC), and matching-adjusted indirect comparison (MAIC)]; 
and (ii) assess technology appraisals (TAs) submitted to the National Institute of 
Health and Carel Excellence (NICE) to determine whether these techniques have 
been accepted by reimbursement authorities. Methods: Embase, Medline and 
the Cochrane Library were interrogated to identify publications reporting on the 
use of MAIC or STC. NICE TAs published from 2011-2014 which reported MAIC or 
STC analyses were identified and the critique by the appraisal group was summa-
rised. Results: Six publications reported on the use of MAIC in six indications. 
Results from these analyses concluded that MAIC offered several advantages over 
conventional meta-analysis methods that rely on aggregate data. Findings from the 
review of NICE TAs indicated that these novel statistical techniques have not been 
objeCtives: Patient preferences have implications for treatment decision mak-
ing, treatment adherence and follow-up care. This study aimed to highlight, using 
metastatic breast cancer (mBC) as an example, a method to elicit preferences and, of 
particular novelty, examine individual differences of those preferences. Methods: 
Using mixed methods, a qualitative study (n= 10) of patients with mBC informed 
the development of the preference survey (a cross-sectional Internet survey admin-
istered to women with mBC). Survey participants (N= 181) completed a conjoint 
exercise that included a series of choice questions. Each choice question included a 
pair of hypothetical treatments that were presented in terms of eight safety attrib-
utes, single attributes for effectiveness, dosing regimen, and quality of life. Survey 
choice data were analyzed using hierarchical Bayesian logistic regression models. 
Predicted values from this model were then analyzed to understand individual 
differences in patient preference. Results: Qualitative interviews identified the 
most relevant side effects to include in the choice task (e.g., alopecia, nausea/vomit-
ing, etc.) and reinforced the importance of quality of life when making treatment 
decisions. In the survey data, treatment effectiveness was most strongly associated 
with treatment preference, followed by alopecia, fatigue, neutropenia, and quality 
of life. Predicted values from the choice model enabled preference comparisons 
across treatment experience subgroups (e.g., 6+ rounds of chemotherapy vs. less). 
Preference strength for individual attributes, e.g., side effects was correlated with 
various demographic and health history variables, though only modest associations 
were detected (Pearson rs< 0.25). ConClusions: Understanding patient prefer-
ences provides opportunities for improved care and outcomes. Combining qualita-
tive and quantitative methods in this study allowed for specificity of preferences 
and generalizability (albeit limited). Patient preferences derived across the sample 
informed predicted values from the choice models that can also be used for compar-
ing preferences across subsamples and identifying factors that may be associated 
with certain preferences.
REsEaRch on MEthods – statistical MEthods
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REal-WoRld vERsus RandoMisEd contRollEd tRial data: a casE  
study on thE cost-EffEctivEnEss of laPaRoscoPic suRgERy foR 
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objeCtives: Real-world (observational) data has the potential to address the limita-
tions of randomised controlled trials (RCTs) but presents its own challenges given 
the increased risk of bias. We compared the costs and quality-adjusted life years 
(QALYs) of patients following random vs preference-based allocation and assessed 
the performance of different methods to address these challenges. Methods: The 
REFLUX study was a pragmatic trial in patients with chronic reflux comparing lapa-
roscopic fundoplication (surgery) with medical management (MM) over 5 years of 
follow-up. The trial included randomised and non-randomised preference-based 
allocation. We compared the cost-effectiveness of surgery in the RCT vs preference 
cohorts as unadjusted raw differences, applying methods to handle biases from 
selection and confounding (regression adjustment, propensity score matching and 
instrument variable analysis) and explored the impact of receiving the preferred 
treatment on the results. Results: The preference surgery group accrued greater 
costs and QALYs than the randomised surgery group (£3,524 vs £2,852; 3.723 vs 
3.612 QALYs). The preference MM group had lower costs but slightly better QALYs 
than the randomised MM group (£861 vs £1,415; 3.541 vs 3.411 QALYs). The incre-
mental cost-effectiveness ratio (ICER) for the preference cohorts was similar to 
that obtained in the RCT using the different methods at around £8,000 per QALY 
gained (vs £7,149 in the RCT and £14,632 unadjusted raw differences). Receiving the 
preferred treatment was significantly associated with lower costs and better QALYs 
after adjusting for prognostic variables. ConClusions: Real-word data can be used 
in cost-effectiveness analysis to complement RCT evidence. However, more research 
is needed on how to choose the most appropriate method to adjust for selection 
bias and how to account for patient preferences when making recommendations 
on value for money.
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intEgRating hEalth PsychoMEtRics With hEalth EconoMics: can thE 
‘MaPPing’ toolBox BE ExtEndEd using oRdinal stRuctuRal Equation 
ModEls?
Patton T., Manca A.
University of York, York, UK
objeCtives: Mapping enables the prediction of health-state utility values via health 
outcome measures in trial data using algorithms linking those measures available 
to preference-based measures (PBMs). However, the unusual distributional features 
of PBMs mean that there is no consensus around the most appropriate statistical 
methodology for obtaining mapping algorithms. Existing studies have shown that 
structural equation modelling (SEM) developments open up a range of opportunities 
for effectively analysing PBMs. This study draws upon some of the methodological 
advances around SEMs from other fields in a case study. Progress towards develop-
ing a mapping algorithm for prediction of EQ-5D scores using a disease-specific 
measure, the Seattle Angina Questionnaire (SAQ), is discussed. Methods: EQ-5D 
and SAQ data were obtained from a completed RCT, the RITA-3 trial. Several psycho-
metric analysis approaches were considered to decide which subscales and items of 
the SAQ were likely to be relevant to the model. Several SEMs were specified and the 
first looked at the EQ-5D index values and SAQ subscales as continuous responses in 
a linear regression model. External information about the reliability of the disease-
specific measure was incorporated into this model. The subsequent models looked 
at the specification of outcomes at the item level with an ordinal logistic approach. 
Models were compared in terms of their ability to fit the observed data and their 
predictive performance. Results: Only three of the five subscales of the SAQ were 
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2009 to Dec 2010) and diagnosis of bipolar I mixed disorder (ICD-9-CM: 296.6x) from 
MarketScan® claims databases, yielded 230 ASE, 2726 aripiprazole, 984 olanzap-
ine, 3056 quetiapine, and 1623 risperidone patients. PS were derived using logistic 
regression models for ASE and each AA with baseline demographic and clinical 
characteristics as covariates. PS, inverse probability treatment weight (IPTW: 1/
PS ASE; 1/ (1-PS) AA), and standard mortality ratio weight (SMR: 1 ASE; PS/ (1-PS) 
AA) distributions were evaluated. ASE-AA un-weighted, IPTW, and SMR baseline 
characteristics were compared using standardized differences, chi-squares, and 
t-tests. Results: Un-weighted asenapine patients had pre-index greater bipolar 
I episodes rates, psychiatric drug use, dyslipidemia and obesity (all comparators). 
PS distributions for asenapine-olanzapine overlapped to some degree while PS of 
asenapine and the other comparators overlapped little to not at all. Comparing IPTW 
baseline characteristics, asenapine more resembled the AA cohorts. Demographic 
imbalance increased between asenapine and each AA. IPTW improved clinical char-
acteristic balance for asenapine versus olanzapine and risperidone, but only slightly 
improved imbalance versus aripiprazole and quetiapine. However some clinical 
characteristics not previously balanced in the un-weighted analyses for asenapine 
versus each AA were now imbalanced. Applying SMR, AA cohorts more resembled 
the asenapine cohort and all baseline demographic and clinical characteristics 
were finally balanced. ConClusions: SMR, a less common PS method, resulted 
in balanced baseline characteristics. SMR should be considered when IPTW leaves 
imbalance and the cohort of primary interest differs significantly from the broader 
underlying population to which it’s being compared.
PRM194
task-BasEd vERsus casE-BasEd analysis of tiME outcoMEs in 
Multi-countRy tiME and Motion (t&M) studiEs: MEthodological 
considERations and aPPlication
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objeCtives: A challenge in multi-centre Time and Motion (T&M) studies is perform-
ing inferential statistics, in light of hierarchical data. Our objective was to investigate 
two approaches to analyze the data. Methods: Task-based approach analysed 
tasks independently, mean times were summed, and 95% confidence intervals 
(CIs) were computed based on Variance Sum Law I (assuming time is independ-
ent among all tasks). Case-based approach involved imputation for missing time; 
all tasks per observation were summed, and a single time variable was analysed. 
Both approaches were applied to three countries participating in a multi-country 
T&M study comparing intravenous [IV] and subcutaneous [SC] administration 
processes. Absolute and relative differences in country means (case-based minus 
task-based) and the difference in CI range were computed using a random intercept 
model, to account for centre clustering. Results: Mean times were similar for both 
approaches. For IV process, absolute (relative) differences in time were -0.03min 
(-0.1%) in France, -0.77min (-2.3%) in Italy, and -0.07min (-0.3%) in Russia. For SC 
process, results were 0.30min (2.1%) in France, 0.90min (4.5%) in Italy, and 0.01min 
(0.1%) in Russia. The differences in CI range between both approaches were notice-
able: 0.51min (5%) in France, 25.04min (57%) in Italy, and 10.06min (46%) in Russia for 
IV and 4.38min (40%) in France, 0.88min (5%) in Italy, and 8.19min (56%) in Russia for 
SC. ConClusions: The choice of task-based or case-based approach did not impact 
mean process time; however, since task-based approach assumed independence of 
task times, it resulted in much narrower CI range. On the other hand, case-based 
approach eliminates the underestimation of variations, thus may therefore be a 
more optimal choice to analyse time outcomes for complex processes. With only a 
single time variable being analysed, it also allows pooling of data across countries, 
therefore providing more power to generate reliable CIs.
PRM195
gRaPhical intERactivE MEta-analysis ModulE foR facilitating 
EvidEncE-BasEd dEcision Making in hEalth caRE
Spata E.1, Bujkiewicz S.2
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objeCtives: In health technology assessment (HTA) decisions about reimburse-
ment of new health technologies are largely based on effectiveness estimates 
obtained from pre-prepared meta-analysis of evidence from randomised con-
trolled trials. However, there is not always a consensus amongst the decision-
makers about the inclusion criteria of studies into the meta-analysis. Therefore an 
approach that allows stakeholders to manipulate the content of the meta-analysis, 
thus facilitating a critical sensitivity analysis in real time during the decision-
making process, would be valuable from the point of view of the transparency of 
the HTA submissions. A Graphical-User-Interface (GUI) was designed to facilitate 
such a transparent decision-making process. Methods: The GUI was designed 
using freely available software packages which included WinBUGS for develop-
ment of meta-analysis and meta-regression models and R which was used to 
design GUI, to link data with statistical models in WinBUGS and to extract the 
results. R was also used to develop graphical tools for presentation of results (for-
est and bubble plots) and for visual assessment of publication bias (funnel plots). 
Software was designed for an illustrative example in rheumatoid arthritis where 
effectiveness of TNF-alpha inhibitors was measured on different scales (DAS-
28, HAQ, ACR, and EULAR). Results: R-based Transparent Interactive Decision 
Interrogator (R-TIDI) was developed, which is a user-friendly tool with “point and 
click” options that allows users to choose an outcome measure and run random-
effects or fixed-effects meta-analysis and meta-regression models. Users are not 
required to have knowledge of statistical software or programming skills since 
the use of WinBUGS and R is entirely “behind the scenes”. R-TIDI enables users to 
interactively include/exclude studies from the meta-analysis allowing for conduct-
ing sensitivity analyses in real time. ConClusions: R-TIDI is a useful tool for 
non-statistical decision-makers. It allows users to run sensitivity meta-analyses 
widely used in manufacturers’ submissions to date. Of the most recent 60 NICE 
TAs, analyses employing MAIC methodology have been presented in two submis-
sions and a STC analysis in a single HTA, all in the oncology setting. In all cases 
the review group identified limitations with the statistical methodology presented, 
although their use as exploratory analyses supporting results from conventional 
meta-analyses was highlighted in one submission. In particular the use of non-
randomised data from single treatment arms was highlighted as a potential weak-
ness of STC. ConClusions: In spite of the increasing published evidence base 
reporting on MAIC in a range of indications, both MAIC and STC have not been 
widely used in manufacturer’s submission to NICE. Assessment bodies critiquing 
the technology submissions remain to be convinced of the appropriateness of these 
novel techniques for the robust assessment of relative efficacy.
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McMc chain?
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objeCtives: Meta-analysis is often conducted in OpenBUGS. This software, like 
all BUGS projects, is based on MCMC simulations by using Gibbs sampling. One 
of the main issues in the use of Markov chains in a continuous space is the chain 
convergence. If the chain does not converge, transient states will be accounted for 
in our posterior distributions. Since these states are not bound to the empirical data 
but only with the chain’s starting point, the estimated parameters of the posterior 
distribution will be biased. To help assessing the convergence of MCMC chain, sev-
eral methods exist. Methods: Based on the literature, we run several simulation 
scenarios in order to test built-in OpenBUGS graphical methods and to assess the 
power of the “thin” approach, a fixed-step jumping-data method, for convergence. 
Then, we focus on the existing diagnoses, their supplementary assumptions and 
their associated computation costs. To help perform these diagnoses directly on 
BUGS objects, we present the R-package coda. Results: The use of jumping-data 
method leads to loss of power and a poorer estimation of posterior distribution 
even in case of high autocorrelation. Consequently, the use of the thin method is 
not recommended to obtain a quicker convergence and better posterior distribution 
estimation. We have also seen that although autocorrelogram and trace can be use-
ful to assess convergence, they can lead to misinterpretation in case of extremely 
low number of studies and conclude to convergence. Alternatively, using the Geweke 
diagnosis seems, in terms of computation cost and assumptions, recommended for 
two main advantages: it gives a measure of trust of being in a stationary process and 
very low computation cost. ConClusions: We presented methods to assess con-
vergence of MCMC chains and argued on their pros and cons. The Geweke diagnose 
was found to provide best trade-off between computational cost and interpretability.
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adjusting foR tREatMEnt cRossovER in a tRaMEtiniB MEtastatic 
MElanoMa Rct: idEntifying thE aPPRoPRiatE MEthod
Bell H.1, Latimer N.1, Amonkar M.2, Casey M.2
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objeCtives: Treatment crossover refers to the situation in randomised controlled 
trials (RCTs) where patients randomised to the control group switch onto the experi-
mental treatment. This leads to biased estimates of treatment effects if not appro-
priately controlled for. Several crossover adjustment methods are available, but 
previous research has shown that the optimal adjustment method depends upon 
the characteristics of the trial. This study applies crossover adjustment methods 
to an RCT comparing trametinib to chemotherapy in patients with BRAF V600E/K 
mutation-positive advanced or metastatic melanoma (NCT01245062), and investi-
gates which adjustment method best fits this case study. Methods: The crossover 
adjustment methods applied include the Rank Preserving Structural Failure Time 
Model (RPSFTM), Iterative Parameter Estimation (IPE) algorithm, Inverse Probability 
of Censoring Weights (IPCW) and a two-stage accelerated failure time model estima-
tion procedure. Suitability of each method is compared by assessing the plausibil-
ity of the underlying assumptions of the models in this case study and analysing 
output and performance indicators associated with each method. Results: In the 
primary efficacy population (patients without history of brain metastases) 67.4% of 
chemotherapy patients switched onto trametinib. The intention to treat (ITT) hazard 
ratio (HR) for overall survival (OS) was 0.72 (95% CI 0.52-1.01). Point-estimates of 
the adjusted HRs produced by the most plausible applications of the RPSFTM, IPE, 
IPCW and two-stage methods ranged between 0.43 and 0.49, consistently favouring 
trametinib. Results were sensitive to the technique used to apply each method. Key 
issues included recensoring, the active nature of the comparator, and the choice of 
covariates included in the analyses. ConClusions: Each of the crossover adjust-
ment methods result in a lower HR than the ITT analysis. However, results are 
uncertain and sensitive to key assumptions. It is important to carefully analyse trial 
characteristics and model output when identifying which applications of adjust-
ment methods are most plausible.
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objeCtives: Asenapine (ASE), an oral Atypical Antipsychotic (AA), was initially used 
for more severe bipolar I mixed disorder. Different propensity score (PS) methods 
were investigated to achieve balanced baseline characteristics between ASE and 
four oral AA cohorts for eventual outcomes analyses. Methods: Adults with ≥ 1 
asenapine, aripiprazole, olanzapine, quetiapine, or risperidone prescription fill (Aug 
